Ibogaine Treatment Memphis, TN: New Law, Cost, Clinics

Ibogaine Treatment Memphis: Tennessee Passed an Ibogaine Law — Here Is What It Actually Does

Tennessee now has an ibogaine statute. The HOPE Treatment Act was signed by the Governor on 22 May 2026, became Public Chapter 1119, and took effect on 1 July 2026. It is real law, and Memphis is unusually well placed to benefit from it.

It also does not let you get ibogaine. It builds a route for Tennessee institutions to run FDA-authorised clinical trials, and the first administrative deadline in it passed less than two weeks ago. If you need treatment now, the legal option is still a medically supervised clinic in Mexico.

Psychedelic Connect is a treatment advisory service. We help Memphis and Shelby County patients understand what is real and, where ibogaine is appropriate, connect them with vetted clinics. Call (866) 435-7057 or request a consultation to speak with a patient coordinator.

Before planning anything, see what ibogaine treatment costs.

Can You Get Ibogaine Treatment in Memphis?

No. Ibogaine is Schedule I under federal law, and the HOPE Treatment Act did not change that. No clinic in Memphis or anywhere in Tennessee can administer it outside an FDA-authorised trial, and no such trial is yet running. Legal, medically supervised treatment means travelling abroad.

A Tennessee law that mentions ibogaine is not permission to receive ibogaine. Anyone in Memphis advertising local ibogaine treatment on the strength of the new act is misreading it, or counting on you not to read it.

What Is Tennessee’s HOPE Treatment Act?

The “Helping Open Pathways to Effective (HOPE) Treatment Act” creates a framework for Tennessee institutions to run ibogaine drug-development clinical trials. It works through “cohorts” — each must include a drug developer, a research institution and a hospital — and state money only flows once non-state matching funds are verified.

The act was codified as a new chapter of Title 33 of the Tennessee Code. Its substance:

• Who can apply. A cohort must include one or more of each of: a drug developer (a pharmaceutical company, biotechnology company or contract development and manufacturing organisation), a research institution, which may be an institution of higher education, and a hospital.
• Who leads. The cohort selects a project lead, and the act states the General Assembly’s intent that the research institution be that lead.
• Matching funds required. The department “shall not disburse funds” to a selected cohort until it verifies receipt of matching funds from sources other than the state.
• FDA first. Once a cohort is selected, it must submit an investigational new drug application to the FDA as soon as practicable. Nothing happens without federal authorisation.
• Who administers it. The Department of Mental Health and Substance Abuse Services.
• “Ibogaine” is defined broadly — ibogaine and ibogaine-based therapeutics, including ibogaine analogs.

The act’s preamble is candid about why: ibogaine’s Schedule I status makes research difficult and, in the General Assembly’s own words, forces patients to seek unregulated treatment abroad. It also cites the Texas research consortium and the Stanford work on veterans.

Source: Tennessee General Assembly, SB 2149 / HB 2075, 114th General Assembly; signed 22 May 2026, Public Chapter 1119, effective 1 July 2026. Accessed 12 September 2026.

Has Anything Happened Under the Act Yet?

The first deadline has just passed. The act required the Department of Mental Health and Substance Abuse Services to begin accepting proposals from cohorts no later than 1 September 2026. That date is now behind us; selection, matching funds and an FDA application all still lie ahead.

That sequence is worth holding onto, because each step takes months and any one of them can stall:

1. The department opens proposals — due by 1 September 2026.
2. A cohort is selected and contracts with the department.
3. The cohort raises matching funds from non-state sources, and the department verifies them before releasing any money.
4. The cohort files an investigational new drug application with the FDA.
5. If the FDA authorises it, a trial is designed, ethics approval is obtained, and only then does anyone enrol.

One correction, since it is circulating: some coverage describes the act as creating a council with appointments due by 1 September 2026. The enacted text contains no council and no appointments. It creates cohorts, and 1 September was the date the department had to start accepting their proposals.

If you are in opioid dependence in Memphis today, this is a process to watch, not a plan to wait on.

Could a Memphis Institution Lead a Tennessee Trial?

Memphis is arguably the best-positioned city in the state. The act defines an eligible institution of higher education as one operated by the University of Tennessee system board of trustees, the board of regents or a state university board — and the University of Tennessee Health Science Center, the UT system’s academic health campus, is in Memphis.

The act also requires a hospital in every cohort, and Memphis has a dense concentration of major hospital systems alongside that academic health campus. A cohort of a drug developer, UTHSC and a Memphis hospital would satisfy the statute’s structure exactly, with the research institution as project lead just as the General Assembly intended.

That is an observation about eligibility, not an announcement. No cohort has been selected, and we are not going to imply that a Memphis trial exists or is promised. But if you are a Memphis patient wondering whether any of this will ever touch your city, the answer is that the statute was written in a way your city fits.

What Does Tennessee’s Overdose Data Say About Ibogaine’s Fit?

Tennessee’s crisis is severe and majority-opioid, which is where ibogaine’s evidence is strongest — but stimulants were involved in 59% of deaths, and ibogaine does little for those. Most people who died were alone.

From the Tennessee Department of Health’s State Unintentional Drug Overdose Reporting System annual report covering 2019–2022:

• Recorded overdose deaths increased 90% between 2019 and 2022.
• In 2022, illicit opioids were involved in 75% of deaths and stimulants in 59%. Fentanyl was the most frequently occurring substance on toxicology.
• The age-adjusted death rate for Black Tennesseans rose 185% between 2019 and 2022 — the sharpest increase of any group.
• The largest increase by age was among people aged 35 to 44.
• Most decedents died at home, and only 23% had a bystander present who could have intervened.
• Only 24% of deaths showed evidence of naloxone having been administered.

Two things follow. First, on substance fit: ibogaine’s best-documented effect is interrupting opioid withdrawal, and there is no equivalent stimulant withdrawal for it to interrupt. With stimulants in 59% of Tennessee overdose deaths, a large share of people here are dealing with something ibogaine addresses only partly. See ibogaine for opioid dependence and ibogaine and stimulants.

Second, the 23% and 24% figures are the most actionable numbers on this page. Arranging ibogaine treatment takes weeks. Keep naloxone in the house, make sure someone knows when you are using, and do not use alone. That advice does not sell anything, and it is the part most likely to matter before any appointment.

Source: Tennessee Department of Health, SUDORS Annual Report (2019–2022). County-level breakdowns for Shelby County are not published in that report, so no Memphis-specific count is given here.

What Happens Before You Travel?

Screening comes first. Ibogaine affects heart rhythm, so clinics require an ECG and bloodwork, a full medication review and a medical history before accepting anyone. Some people are screened out — and being told no is the system working.

• Initial conversation — what you are treating, what you have already tried, current medications and doses.
• Medical screening — ECG, liver and kidney panels, electrolytes. Some medications, particularly certain antidepressants and long-acting opioids, need a supervised taper arranged well beforehand.
• Clinic matching — facilities whose medical model fits the presentation, not whichever one has a bed free.
• Treatment — most programmes run seven to ten days.
• Integration — the part that decides whether the result holds. See integration therapy after ibogaine.

If you are in acute withdrawal or crisis right now, call 988 or 911. Ibogaine requires weeks of preparation and cannot be accessed on an emergency timeline.

Getting from Memphis to a Mexican Clinic

Memphis International connects to Mexico through Dallas–Fort Worth, Houston or Atlanta rather than directly, so most Memphis patients fly one leg to a hub and one leg on. Cancún holds the largest concentration of established ibogaine clinics; Baja California clinics near Tijuana and Rosarito are usually reached via a San Diego connection and take longer from this part of the country. Schedules shift seasonally, so we check current routing with you rather than printing a flight time that goes stale.

Travel time is the least important variable in this decision. Programme length, whether a physician is on site overnight, what screening is required before you fly, and whether integration is included matter far more to the outcome.

What About Memphis Veterans?

Several clinics in our network run protocols built for combat-related PTSD, traumatic brain injury and co-occurring substance use. The VA cannot provide ibogaine — it is Schedule I, and a state law does not change federal scheduling.

The Memphis VA Medical Center serves veterans across west Tennessee, northern Mississippi and eastern Arkansas, and can treat much of what people seek ibogaine for through means that are legal here. The Stanford research the HOPE Act’s own preamble cites was conducted in veterans who had travelled abroad for treatment — which is exactly the situation Tennessee legislators said they wanted to make unnecessary. See ibogaine for veterans.

What Does Treatment Cost for Tennessee Patients?

Between $5,000 and $15,000, depending on length of stay and facility. Insurance does not cover it, because ibogaine is Schedule I in the United States. Budget separately for flights and for integration support afterwards.

The range reflects real differences: programme length, whether a physician is on site around the clock, the level of cardiac monitoring, private versus shared accommodation, and whether integration is bundled. A price well below that range usually means fewer medical staff, which is the wrong place to economise on a drug with known cardiac risk.

A trial under the HOPE Act, if one ever runs, would not bill participants. It also does not exist yet, and the statute’s own sequence puts an FDA application ahead of any enrolment.

What Psychedelic Connect Does

We are a treatment advisory service, not a clinic. We do not administer ibogaine and we do not own a facility. We help you work out whether ibogaine is reasonable in your specific case, and if it is, which clinic fits.

We visit the clinics we recommend — we look at medical staffing, monitoring equipment, what happens overnight, and what a facility does when something goes wrong. We are guided by people who get it, including clinicians and people who have been through this themselves. Our clinical content is reviewed by Christopher Diviaio, LCSW. If you want to pressure-test any provider, including us, our guide on how to vet an ibogaine provider lists the questions worth asking.

Resources in Memphis and Shelby County:

• SAMHSA National Helpline: (800) 662-4357 — 24/7 treatment referral (samhsa.gov)
• 988 Suicide & Crisis Lifeline: call or text 988
• Veterans Crisis Line: 988, then Press 1
• Tennessee REDLINE: (800) 889-9789 — 24/7 confidential substance use referral

Consultation — Call Today

If you are in Memphis, Germantown, Bartlett, Collierville, Southaven or anywhere in the Mid-South, call (866) 435-7057 to talk with a patient coordinator. You can also start with our online form and we will follow up within one business day.

Medical Disclaimer: Psychedelic Connect is a treatment advisory service. We do not provide medical advice. Ibogaine treatment involves serious medical considerations including cardiac risks. Always consult a qualified medical professional before pursuing any treatment.

Frequently Asked Questions — Ibogaine Treatment, Memphis and Tennessee

Is ibogaine legal in Tennessee?
No. Ibogaine remains a Schedule I controlled substance under federal law. Tennessee’s HOPE Treatment Act, signed 22 May 2026 as Public Chapter 1119 and effective 1 July 2026, authorises Tennessee cohorts to pursue FDA-authorised ibogaine clinical trials. It does not permit treatment outside such a trial, and no trial is yet running.

When could a Tennessee ibogaine trial begin enrolling?
No date can honestly be given. The department had to begin accepting cohort proposals by 1 September 2026. A cohort must then be selected, raise and verify non-state matching funds, and file an investigational new drug application with the FDA before any trial is designed or anyone is enrolled.

Does the HOPE Act create a council?
No. The enacted text creates no council and provides for no appointments. It establishes “cohorts” made up of a drug developer, a research institution and a hospital, with the research institution intended as project lead. Coverage describing a council with September appointments does not match the statute.

Does ibogaine work for methamphetamine or cocaine addiction?
The evidence is much weaker than for opioids, and that matters in Tennessee, where stimulants were involved in 59% of overdose deaths in 2022 against illicit opioids in 75%. Ibogaine’s best-documented effect is interrupting opioid withdrawal, and there is no equivalent stimulant withdrawal for it to interrupt.

What should I do while I plan treatment?
Keep naloxone accessible and do not use alone. Tennessee’s own overdose data found that most people who died did so at home, only 23% had a bystander present who could have intervened, and only 24% had any evidence of naloxone being administered. Arranging ibogaine takes weeks, and those weeks are when the risk is.

How dangerous is ibogaine?
It carries real cardiac risk, which is why legitimate clinics require an ECG and bloodwork beforehand and why a facility without a physician on site should be ruled out. The published evidence for opioid dependence is promising but limited — mostly observational studies with small numbers and no control group. That is precisely why Tennessee legislated for trials rather than for treatment.

Psychedelic Connect · (866) 435-7057 · contact@psychedelic-connect.com

Published 12 September 2026 · Last updated 12 September 2026 · Clinical review: Christopher Diviaio, LCSW